INVO Fertility, Inc. (INVO) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by INVO Bioscience, Inc. (trading as INVO Fertility, Inc.) on September 30, 2020, reporting events occurring on September 24, 2020. The filing details a strategic expansion into the Mexican market through a new joint venture structure.
Key Financial Metrics
The filing text does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a material definitive agreement and does not contain audited or unaudited financial statements.
Material Changes and Agreements
On September 24, 2020, INVO Centers, LLC (a wholly-owned subsidiary of INVO Bioscience, Inc.) entered into a Pre-Incorporation and Shareholders Agreement with Francisco Arredondo, MD PLLC and Security Health LLC. Key terms include:
- Joint Venture Formation: The parties intend to establish a Mexican company named "Positib Fertility, S.A. de C.V." within three weeks of the agreement.
- Ownership Structure: INVO Centers, Arredondo, and Ramirez will hold equal 1/3 equity shares in the new Mexico Company.
- Operations: The entity will commercialize the INVO IVC procedure and offer related medical treatments, initially operating in Monterrey, Nuevo Leon, Mexico.
- Product Supply: The Mexico Company will acquire the INVOcell product exclusively from INVO Bioscience, Inc. at cost plus uncured shipping, customs, and related fees.
- Exclusivity: The Mexico Company is designated as the exclusive distributor of INVO products in Mexico, with shareholders agreeing not to compete directly or indirectly in the region.
Outlook, Risks, and Management Commentary
Management views this agreement as a step to expand the commercialization of the INVO IVC procedure internationally. The filing references a press release issued on September 30, 2020, titled "INVO Bioscience Establishes Joint Venture to Operate Dedicated INVOcell Fertility Clinics in Mexico." No specific financial guidance or quantitative risk factors regarding the venture's profitability were disclosed in this text.
Investor Verification Checklist
- Verify the successful incorporation of "Positib Fertility, S.A. de C.V." within the stipulated three-week timeframe.
- Review the full text of the Pre-Incorporation and Shareholders Agreement (Exhibit 10.1) for specific governance rights and exit strategies.
- Confirm regulatory approvals required to operate fertility clinics in Monterrey and other Mexican cities.
- Monitor future filings for financial impact, specifically regarding the "cost plus" supply arrangement and potential revenue recognition from the joint venture.